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Abstract
We previously demonstrated that the sodium/hydrogen exchanger NHA2, also known as
NHEDC2 or SLC9B2, is critical for insulin secretion by β–cells. To gain more insights into
the role of NHA2 on systemic glucose homeostasis, we studied the impact of loss of NHA2
during the physiological aging process and in the setting of diet-induced obesity. While glu-
cose tolerance was normal at 2 months of age, NHA2 KO mice displayed a significant glu-
cose intolerance at 5 and 12 months of age, respectively. An obesogenic high fat diet
further exacerbated the glucose intolerance of NHA2 KO mice. Insulin levels remained sim-
ilar in NHA2 KO and WT mice during aging and high fat diet, but fasting insulin/glucose
ratios were significantly lower in NHA2 KO mice. Peripheral insulin sensitivity, measured by
insulin tolerance tests and hyperinsulinemic euglycemic clamps, was unaffected by loss of
NHA2 during aging and high fat diet. High fat diet diminished insulin secretion capacity in
both WT and NHA2 KO islets and reduced expression of NHA2 in WT islets. In contrast,
aging was characterized by a gradual increase of NHA2 expression in islets, paralleled by
an increasing difference in insulin secretion between WT and NHA2 KO islets. In summary,
our results demonstrate that loss of the sodium/hydrogen exchanger NHA2 exacerbates
obesity- and aging-induced glucose intolerance in mice. Furthermore, our data reveal a
close link between NHA2 expression and insulin secretion capacity in islets.
Introduction
Sodium/hydrogen exchangers (NHEs) are ion transport proteins found across all phyla of uni-
and multicellular organisms and exchange monovalent cations with protons across lipid bilayers.
In mammals, 13 NHE isoforms are currently known [1,2]. NHA2, also known as SLC9B2 or
NHEDC2, is a recently cloned, poorly characterizedNHE isoform [3]. Previous studies suggested
PLOS ONE | DOI:10.1371/journal.pone.0163568 September 29, 2016 1 / 12
a11111
OPENACCESS
Citation: Deisl C, Anderegg M, Albano G, Lu¨scher
BP, Cerny D, Soria R, et al. (2016) Loss of Sodium/
Hydrogen Exchanger NHA2 Exacerbates Obesity-
and Aging-Induced Glucose Intolerance in Mice.
PLoS ONE 11(9): e0163568. doi:10.1371/journal.
pone.0163568
Editor: Kathrin Maedler, University of Bremen,
GERMANY
Received: June 21, 2016
Accepted: September 11, 2016
Published: September 29, 2016
Copyright: © 2016 Deisl et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the Swiss
National Centre of Competence in Research
(NCCR) TransCure, the Swiss National Science
Foundation (grants # 31003A_135503 and #
31003A_152829) and by a Medical Research
Position Award of the Foundation Prof. Dr. Max
Cloe¨tta. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
89
09
1 
| 
do
wn
lo
ad
ed
: 
3.
10
.2
01
6
that NHA2 is the correlate of the long sought sodium/lithiumcountertransporter that was linked
to the pathogenesis of diabetesmellitus and essential hypertension in humans [2,4,5].
While NHA2 is ubiquitously expressed on tissue level, it is mainly confined to specialized
cells within individual organs, e.g. osteoclasts in the bone or distal tubules of the kidney [4,6,7].
We recently reported that NHA2 is present in human and rodent β-cells of the endocrine pan-
creas [8]. Islets isolated fromNHA2 knock-out (KO) mice displayed an insulin secretion deficit
upon stimulation with glucose or the sulfonylurea tolbutamide. Similar findings were obtained
when NHA2 was knocked-downby RNA interference in the murine β–cell line Min6 [8].
Confocalmicroscopy and subcellular fractionation studies revealed that NHA2 localizes to
endosomal structures in β–cells, and depletion or loss of NHA2 caused inhibition of clathrin-
dependent endocytosis in primary β–cells and Min6 cells [8]. Given the known tight interac-
tion of endo-and exocytosis in β–cells, these results suggested that disrupted endo-exocytosis
coupling may be the primary cause for the insulin secretion deficit observed [9,10]. The exact
role of NHA2 in β–cell endosomes, however, remains unclear at the moment, but seems not to
involve endosomal pH homeostasis [8].
To gain more insights into the role of NHA2 on systemic glucose homeostasis, we studied
the impact of NHA2 deficiencyduring the physiological aging process and in the setting of
diet-induced obesity.
Materials and Methods
Mice
All animal experiments were in accordance with the Swiss AnimalWelfare Law and were
approved by the local Veterinary Authority (Veterinary Office of the Kanton Bern).Mice had
free access to water and chow and were maintained on a 12 hours light/12 hours dark cycle at
room temperature (23°C). Normal diet (F1850; 20.5% protein, 7.2% fat, 61.6% carbohydrate)
and high fat diet (F3282; 20.5% protein, 36% fat, 35.7% carbohydrate) were purchased from
Bio-Serv, Frenchtown, NJ. Both diets were otherwise identical.
Generation of NHA2 KO mice lacking exon 7 of theNHA2 gene was described in detail pre-
viously [8]. All mice used in this study were males and completely backcrossed into C56BL/6J
background (> 10 generations). Completeness of backcrossing was verified by microsatellite
marker analysis, as described [8].
Intraperitoneal glucose (IPGTT) and insulin (IPITT) tolerance tests
Blood glucose and serum insulin concentrations were measured in male mice of indicated age
after a 6 to 12 AM 6 hr fast (ip. glucose tolerance test) or at random fed state at 2 PM (ip. insu-
lin tolerance test) as described [8,11,12]. Blood glucose was measured before and after intraper-
itoneal injections of glucose (2g/kg or 1 g/kg) or insulin (1 U/kg Actrapid HM, Novo Nordisk,
Denmark) with a Contour glucosemonitor (Bayer Healthcare, Germany) by tail vein sampling
at indicated time points in duplicates. The upper detection limit of the glucosemonitor used
was a glucose concentration of 33.3 mmol/L, values exceeding this limit were counted as 33.3
mmol/l. Serum insulin (CrystalChem,Downers Grove, IL, USA), serum leptin (CrystalChem),
serum adiponectin (CrystalChem)and plasma glucagon (Mercodia, Uppsala, Sweden) concen-
trations were determined by ELISAs.
Hyperinsulinemic euglycemic clamp studies
Hyperinsulinemic euglycemic clamp studies were performed as described [13]. Clamps were
done in freely moving mice after 12 weeks of high fat diet. Three days before the clamp studies,
NHA2 and Insulin Secretion in Islets
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mice were anesthetized with isoflurane, and an indwelling catheter to be used for insulin infu-
sion was inserted into the vena cava through the femoral vein, sealed under the back skin, and
exteriorized and glued at the back of the neck. On the day of the clamp, after a 6-hour fast,
insulin (18 mU x kg-1 x min-1, a dose known to suppress hepatic glucose production) was
infused into the femoral vein for 2 hours. Throughout the infusion, blood samples (3.5 μL)
were collected every 10 minutes from the tip of the tail vein for the determination of the blood
glucose concentration, and euglycemia (5.5 mmol/l) was maintained by periodic adjustment of
a variable infusion of 15% glucose. The steady state glucose infusion rate was calculated as the
mean of the values obtained every 5 minutes during the last 30 minutes of the clamp.
Isolation of islets and in vitro insulin release assays
Pancreata were perfused in situ with collagenase solution and islets isolated exactly as described
[8,14]. After overnight incubation in RPMImediumwith 11 mM glucose, islets were washed
twice with KRBH containing 2 mM glucose and then placed in 12-well plates (10 islets/well)
containing 1 ml of KRBHwith 2 mM glucose and pre-incubated for 2.5 hrs at 37°C. Insulin
secretion into the KRBH buffer was measured for 2 hrs. After this time, supernatants were har-
vested, plates put on ice and total cellular insulin extracted by addition of acid ethanol (70%
ETOH, 1.5% HCL conc.). Secreted and cellular insulin (CrystalChem)was determined by
ELISA.
Total liver lipid extraction
Liver tissue (30 mg) was homogenized in 1x PBS and lipids were extracted in a chloroform/
methanol (2:1) mixture. Total liver lipids were determined by a sulpho-phospho-vanillin reac-
tion as describedpreviously [15,16].
RNA isolation and real-time PCR
RNA isolation was performed using Trizol reagent (ThermoFisher Scientific,Waltham, MA,
USA) as described [5,8]. Real-time PCR was performed using pre-synthesized Assays-on-
Demand (AoD; Life Technologies/ABI, Rotkreuz, Switzerland) on an ABI ViiA 7 System. The
following AoDs were employed: NHA2 (Mm01313329_m1), GAPDH (Mm99999915_g1). The
amount of NHA2 relative to GAPDHmRNA was calculated using the ΔCt method.
Statistical Analysis
Statistical significancemeasurements were performed by Student t test or one-way ANOVA
for multiple comparisons. All statistical tests were two-sided and a p< 0.05 was considered sta-
tistically significant. Data are shown as means and error bars indicate SEs.
Results
Loss of NHA2 KO worsens aging-induced glucose intolerance in mice
To study the age-dependent impact of NHA2 gene inactivation on glucose homeostasis, we
studied 3 different groups of male mice, aged 2, 5 and 12 months, respectively. All mice were
males in a C57BL6/J background and either wild-type (WT) or bearing a targeted mutation in
theNHA2 gene (NHA2 KO) [8]. As shown in Fig 1A, 1D and 1E fasting blood glucose was not
different between 2 months old WT and NHA2 KO mice and an intraperitoneal glucose load
(IPGTT) of 2 g/kg body weight caused similar glycemic excursions and insulin levels in both
groups of mice. In 5 months old mice, however, we observed clear differences between the two
groups of mice (Fig 1B and 1D). NHA2 KO mice displayed higher fasting glucose and
NHA2 and Insulin Secretion in Islets
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significantly higher glycemic excursions after i.p. glucose challenge (2 g/kg body weight) com-
pared toWTmice. Serum insulin was significantly lower in the fasting state, 15 and 120 min-
utes after glucose challenge. Glucose challenge in 12 months old mice was performedwith a
reduced dose of glucose (1g/kg body weight), because 2g/kg body weight induced blood glucose
levels in NHA2 KO mice that were consistently exceeding the measurable range of the glucose
meter. Blood glucose was significantly higher in 12 months old NHA2 KO mice compared to
WTmice in the fasting state and up to 30 minutes after glucose administration (Fig 1C and
1D). Serum insulin levels, however, were not different in 12 months old NHA2 KO mice com-
pared toWTmice (Fig 1G). Basal versus peak insulin ratios during the IPGTTs were not differ-
ent between the two groups of mice at all ages (Fig 1H).
Fasting insulin/glucose ratios at 2 months of age were similar in both groups of mice but sig-
nificantly lower in NHA2 KO mice at 5 and 12 months of age (Fig 1I). Thus, in a next step, we
tested the peripheral insulin sensitivity by intraperitoneal insulin tolerance tests (1 U /kg body
weight). However, at all ages, sensitivity of NHA2 KO mice to insulin was not different from
WTmice (Fig 2A–2D). However, 120 minutes after insulin administration, significant but
opposite differences in blood glucose betweenNHA2 WT and KO mice were observed in 2 and
12 months old mice, respectively (Fig 2A and 2C). Such variations maybe be due to an altered
counterregulatory response during hypoglycemia. To exclude that loss of NHA2 affects gluca-
gon secretion by α-cells, we measured plasma glucagon at baseline and 30 minutes after insulin
Fig 1. Intraperitoneal glucose tolerance tests in NHA2 WT and KO mice fed normal chow diet at different ages. A) Blood glucose concentrations
following ip. glucose challenge (2g/kg body weight) at 2 months; n+/+ = 8, n-/- = 8. B) Blood glucose concentrations following ip. glucose challenge (2g/kg
body weight) at 5 months; n+/+ = 9, n-/- = 9. C) Blood glucose concentrations following ip. glucose challenge (1g/kg body weight) in 12 months old mice; n+/+ =
9, n
-/- = 9. D) Area under the curve (AUC) of intraperitoneal glucose tolerance tests (IPGTT) at 2, 5 and 12 months of age. E) Serum insulin concentrations
following ip. glucose challenge (2g/kg body weight) at 2 months; n+/+ = 8, n-/- = 8. F) Serum insulin concentrations following ip. glucose challenge (2g/kg body
weight) at 5 months; n+/+ = 9, n-/- = 9. G) Serum insulin concentrations following ip. glucose challenge (1g/kg body weight) at 12 months; n+/+ = 9, n-/- = 9. H)
Peak (15 minutes) to basal (0 minutes) insulin ratios during ip. glucose challenges at 2, 5 and 12 months of age. I) Fasting insulin to glucose ratios at 2, 5 and
12 months of age. Data are mean values ± SEM, (* p<0.05, WT vs KO; NS = not significant, WT vs KO).
doi:10.1371/journal.pone.0163568.g001
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administration. (Fig 2E and 2F). Plasma glucagon was significantly elevated at 30 minutes com-
pared to baseline. The increase was more pronounced in the 2 months old mice, in agreement
with the more pronounced hypoglycemia induced by insulin administration. At both time
points, however, we detected no differences betweenNHA2 WT and KO mice, indicating that
loss of NHA2 does not alter hypoglycemia-induced glucagon release.
Together, our experiments indicate that loss of NHA2 exacerbates aging-associated glucose
intolerance in mice.
Loss of NHA2 KO worsens obesity-induced glucose intolerance in mice
We next sought to investigate the role of NHA2 during diet-induced obesity. To this end, 8
week old male C57BL6/JWT or NHA2 KO mice were placed on an obesogenic high-fat diet
(HFD) for 12 weeks [17]. As shown in Fig 3A, WT and NHA2 KO mice displayed comparable
weight gains throughout the HFD. There was also comparable linear growth in both groups of
mice and thus no differences were apparent in the bodymass index (BMI, g/cm2) at the end of
the HFD period (Fig 3B and 3C). Similarly, organ weights and total hepatic lipid content of
mice sacrificed at 5 months of age after 12 weeks of HFD revealed no differences betweenWT
and NHA2 KO mice (Fig 3D and 3E). In addition, we observedno differences in the size of
inguinal, epididymal and retroperitoneal fat pads (Fig 3D). DuringHFD, fasting blood glucose
and fasting insulin levels were measured every two and four weeks, respectively (Fig 3F and
3G). As shown in Fig 3F, fasting blood glucose levels rose continuously with duration of HFD
in both groups of mice. Beyondweek 8 on HFD, fasting blood glucose was consistently higher
in the NHA2 KO mice compared toWTmice (Fig 3F). Fasting serum insulin tended to be
Fig 2. Intraperitoneal insulin tolerance tests in NHA2 WT and KO mice fed normal chow diet at different ages. A) Blood glucose concentration in % of
baseline glucose following ip. insulin challenge (1 U/kg body weight) at 2 months; n+/+ = 10, n-/- = 10. B) Blood glucose concentration in % of baseline glucose
following ip. insulin challenge (1 U/kg body weight) at 5 months; n+/+ = 11, n-/- = 12. C) Blood glucose concentration in % of baseline glucose following ip.
insulin challenge (1 U/kg body weight) at 12 months; n+/+ = 9, n-/- = 12. D) Area under the curve (AUC) of intraperitoneal insulin tolerance tests (IPITT) at 2, 6
and 12 months of age. E) Plasma glucagon concentration at baseline and 30 minutes after ip. administration of insulin (1 U/kg body weight) in 2 months old
mice. F) Plasma glucagon concentration at baseline and 30 minutes after ip. administration of insulin (1 U/kg body weight) in 12 months old mice. Data are
mean values ± SEM, (* p<0.05, WT vs KO; NS = not significant, WT vs KO).
doi:10.1371/journal.pone.0163568.g002
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lower throughout the HFD period in NHA2 KO mice, but the differences did not reach statisti-
cal significance.While the fasting insulin/glucose ratio was similar in both groups of mice at
baseline, we found it to be significantly lower in NHA2 KO mice at 4, 8 and 12 weeks of HFD
(Fig 3H).
As observedon regular chow, on HFDNHA2 KO mice displayed a fasting plasma glucagon
that was not different fromWTmice on HFD (Fig 3I).
Given the widespread tissue distribution of NHA2, we next tested if, in addition to insulin
secretion, loss of NHA2 affects secretion of other peptide hormones involved in glucose
homeostasis. For this, we quantified concentrations of the two major adipokines leptin and
Fig 3. High fat diet in NHA2 WT and KO mice. A) Weight gain of mice during 12 weeks of HFD. HFD was started at 8 weeks of age. B) Nasal to anal length
at week 12 of HFD. C) BMI at week 12 of HFD. D) Organ and fat pad weights at week 12 of HFD. E) Hepatic total lipid content at week 12 of HFD. F) Fasting
blood glucose concentration at baseline and at indicated week during HFD. G) Fasting serum insulin concentration at baseline and at indicated week during
HFD. H) Fasting insulin to glucose ratios at indicated time points during HFD. I) Fasting plasma glucagon concentrations at week 12 of HFD. J) Fasting
serum leptin concentrations at baseline and at indicated week of HFD. K) Fasting serum adiponectin concentrations at baseline and at indicated week of
HFD. Data are mean values ± SEM, (* p<0.05, WT vs KO; NS = not significant, WT vs KO).
doi:10.1371/journal.pone.0163568.g003
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adiponectin at baseline and after 8 and 12 weeks of HFD. As shown in Fig 3J and 3K, our
results reveal the well known differential secretion pattern of the two hormones by adipose tis-
sue during HFD [18,19]. However, as is the case for glucagon, leptin and adiponectin secretion
were unaffected by loss of NHA2.
Together these experiments reveal that ectopic lipid deposition, hepatic steatosis and fat
mass gain are similar in NHA2 WT and KO mice during diet-induced obesity. However, lack
of NHA2 causes progressive increase of fasting glycemia with a drop of fasting insulin/glucose
ratios during obesogenicHFD.
We next tested the functional significance of NHA2 inactivation for glucose disposal by per-
forming intraperitoneal glucose challenges (1g/kg body weight) to WT and NHA2 KO mice on
HFD. As depicted in Fig 4A and 4B, WTmice were clearly glucose intolerant after 12 weeks of
HFD, as reported previously [17]. Mice lacking NHA2 had higher fasting glycemia and dis-
played significantly higher glycemic excursion during the glucose challenge thanWTmice.
Serum insulin levels were lower in NHA2 KO mice at 15 and 120 minutes of the IPGTT (Fig
4C). Peak to basal insulin ratio after 12 weeks of HFD was similar in both groups of mice
(Fig 4D).
To evaluate peripheral insulin sensitivity, we next performed hyperinsulinemic euglycemic
clamps onWT and NHA2 KO mice after 12 weeks of HFD. As evidence by the low steady-
state glucose infusion rate, WTmice were insulin resistant after 12 weeks of HFD (Fig 4E).
However, the degree of insulin resistance was identical in NHA2 KO mice, indicating that also
in the setting of diet-induced obesity, loss of NHA2 per se does not alter insulin sensitivity.
Fig 4. Intraperitoneal glucose tolerance test and hyperinsulinemice euglycemic clamp in NHA2 WT and KO mice after 12 weeks of HFD. A) Blood
glucose concentrations following ip. glucose challenge (1g/kg body weight); n+/+ = 12, n-/- = 10. B) Area under the curve (AUC) of the intraperitoneal glucose
tolerance test (IPGTT). C) Serum insulin concentrations following ip. glucose challenge (1g/kg body weight); n+/+ = 12, n-/- = 10. D) Peak (15 minutes) to
basal (0 minutes) insulin ratios after 12 weeks of HFD. E) Glucose infusion rates during hyperinsulinemic euglycemic clamps; n+/+ = 8, n-/- = 8. Data are
mean values ± SEM, (* p<0.05, WT vs KO; NS = not significant, WT vs KO).
doi:10.1371/journal.pone.0163568.g004
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Age- and HFD-dependent changes in WT and NHA2 KO islets
Together, the phenotype observed in aging mice and in mice with diet-induced obesity suggests
that lack of NHA2 causes glucose intolerance, at least partially, due to inappropriate insulin
secretion. Interestingly, however, the phenotype of young 2 months old NHA2 KO mice was
almost indistinguishable fromWTmice, indicating that either well-functioning compensatory
mechanisms are in place or that NHA2 expression is very low in islets at this age. To explore
this in more detail, we next investigated in vitro glucose-induced insulin secretion by islets iso-
lated from 2 and 5 months old mice and from 5 months old mice subjected to a 12 weeks HFD
prior to islet isolation. Insulin secretion was quantified in % of total islet insulin content. As
shown in Fig 5A, islets isolated from 2 months old NHA2 KO mice exhibited a basal insulin
secretion (2 mM glucose) that was not different fromWT islets, but displayed a ~20% reduc-
tion of insulin secretion compared toWT islets in high glucosemedium (20 mM glucose). In
contrast, islets isolated from 5 months old mice displayed ~20% reduced basal insulin secretion
and ~ 45% reduction of insulin secretion in high glucose. The impact of loss of NHA2 in islets of
5 months old mice fed a HFD for 12 weeks prior to islet isolation was evenmore pronounced.
Basal and high glucose-induced insulin secretionwere reduced by ~ 40% and ~60%, respectively
(Fig 5A). Furthermore, in islets isolated from normal chow fedmice, we observedan age-depen-
dent increase of insulin secretion, which was blunted in NHA2 KO islets (Fig 5A). Compared to
islets isolated frommice fed a normal chow diet, we observeda significant reduction of insulin
secretion in bothWT and NHA2 KO islets isolated of HFD fedmice (Fig 5A).
Given the age- and diet-dependent differences in insulin secretion betweenWT and NHA2
KO islets, we next sought to determine the impact of aging and HFD on NHA2 expression in
murineWT islets. As shown in Fig 5B, we observed a continuous, age-dependent increase of
NHA2 expression in islets. In contrast, HFD caused a significant reduction of NHA2 expres-
sion in islets (Fig 5B).
Discussion
In the present study we evaluated the impact of NHA2 deficiency on glucose homeostasis in
mice during physiological aging and diet-induced obesity. Mice used for the study were on a
C57BL6/J background, and HFD-induced changes inWTmice were similar as reported previ-
ously [17,20,21]. Our results indicate that the impact of NHA2 deficiency on glucose
Fig 5. In vitro insulin secretion of NHA2 WT and KO islets. A) Basal (2 mM) and glucose (20 mM) induced insulin secretion of islets isolated from 2 or 5
months old mice fed a normal chow (NFD) or from 5 months old mice fed a high fat diet (HFD) for 12 weeks; n = 300 islets per genotype and condition. Data
are mean values ± SEM, (* p<0.05, WT vs KO; NS = not significant, WT vs KO; # p<0.05, WT vs WT or KO vs KO. B) NHA2 mRNA expression in islets of 2,
3.5, 5 and 12 months old mice fed a normal chow (NFD) or from 5 months old mice fed a high fat diet (HFD) for 12 weeks; n = 300–500 islets of 3–5 mice/
group. Data are mean values ± SEM, (* p<0.05, vs indicated condition; # p<0.05, vs all other conditions).
doi:10.1371/journal.pone.0163568.g005
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homeostasis islets is augmented by aging and obesogenicHFD. Worsened glucose tolerance in
NHA2 KO mice under both conditions was not due to altered peripheral insulin sensitivity.
Furthermore, serum insulin levels were similar in NHA2 KO andWTmice. In contrast, islets
isolated from NHA2 KO mice displayed significant reductions of glucose-induced insulin
secretionwhen compared toWT islets in vitro. These findings suggest the presence of in vivo
compensatory mechanisms for the reduced islet insulin secretion capacity, e.g. a decreased
hepatic insulin clearance or an expansion of islet cell mass in NHA2 KO mice. In addition,
however, despite similar insulin levels, NHA2 KO mice were significantlymore glucose intoler-
ant during aging and HFD and displayed significantly decreased fasting insulin to glucose
ratios compared to WTmice. These results indicate that likely additional, insulin-independent
mechanisms of glucose tolerance are disturbed in NHA2 KO mice under these conditions [22].
Clearly, a β-cell-specificNHA2 KO model, which unfortunately is not available at the moment,
would be very helpful in the differentiation of β-cell-dependent and β-cell -independent roles
of NHA2 in the phenotype observed.
We previously demonstrated that even partial knock-down of NHA2 in Min6 cells or het-
erozygous loss of NHA2 in islets reduces insulin secretion and that insulin secretion could be
rescued by overexpression of WT, but not functionally dead, human NHA2 [8]. These observa-
tions suggested a direct link of NHA2 transport activity with insulin secretion in β–cells.
Results obtained in the current study demonstrate that NHA2 expression increases signifi-
cantly during aging. Furthermore, upregulation of NHA2 expression during aging was paral-
leled by an increased sensitivity of islets towards loss of NHA2, evidencedby an increased
difference of insulin secretion betweenWT and NHA2 KO islets. These results clearly support
the notion of a link betweenNHA2 expression and insulin secretory capacity in islets. Low lev-
els of NHA2 expression in islets at 2 months may also explain the fact that we observedonly
subtle differences in vitro between islets of WT and NHA2 KO mice. During obesogenicHFD,
NHA2 expression but also insulin secretion dropped significantly inWT islets, but the differ-
ence in insulin secretion between the two groups of islets remained large. However, NHA2
expression was still significantly higher in HFD islets than in islets of 2 months old mice. The
NHA2 expression in HFD islets was comparable to 3.5 months old normal chow fed mice,
where we previously found a ~50% reduction of insulin secretion in NHA2 KO islets [8]. HFD-
associated toxicity affects islets on multiple levels by a myriad of factors [23]. It is conceivable
that chronic alterations in NHA2 KO islets render them especially sensitive to HFD-associated
toxicity. Specific pharmacologic inhibition of NHA2 would allow the differentiation of direct
functional consequences from adaptive changes in the islets caused by loss of NHA2 and for-
mally test the concept of a direct link betweenNHA2 function and insulin secretion. Unfortu-
nately, however, such a specificNHA2 inhibitor is not available at the moment. Nevertheless,
our results suggest that a better understanding of the molecularmechanisms governing NHA2
expression in islets may offer opportunities for pharmacologicmodulation of NHA2 expres-
sion and thus insulin secretion in pancreatic β-cells.
Given the wide tissue distribution of NHA2, it was conceivable that loss of NHA2 may also
affect secretion of other peptide hormones engaged in glucose homeostasis, thereby contribut-
ing to the phenotype observed in NHA2 KO mice. Our results, however, indicate that glucagon
and the two major adipokines leptin and adiponectin are not affected by loss of NHA2. Thus,
together, our in vivo and in vitro data indicate that the phenotype of NHA2 KO mice is caused
by direct alterations at the level of the β–cell. Due to the lack of a β-cell specificNHA2 KO
mouse model, however, we currently cannot completely exclude the possibility that humoral or
non-humoral factors outside of the β–cell contribute to the phenotype observed.
Aging and obesity are believed to be the main causes for the increased prevalence of type 2
diabetes in the last decades [24,25]. While the hallmark of type 2 diabetes is resistance to the
NHA2 and Insulin Secretion in Islets
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action of insulin, diminished or inappropriate secretion of insulin is universally present in type
2 diabetics [26]. Defects in insulin secretion occur early in the pathogenesis of type 2 diabetes,
and both reduction in β-cell mass and intrinsic β-cell dysfunction contribute to the defective
insulin secretion in type 2 diabetes [26,27]. There is compelling evidence that genetic factors
affecting insulin secretion contribute to the pathogenesis of type 2 diabetes [28,29]. While the
role of NHA2 in human islets has not been studied to date, human islets exhibit robust NHA2
expression and several single-nucleotide polymorphisms (SNPs) in human NHA2 that alter
the transport characteristics were recently described [8,30]. The phenotype of individuals with
these functionally relevant SNPs in NHA2 has not been studied to date, but these individuals
may be at an increased risk to develop glucose intolerance under certain circumstances (obe-
sity, old age).
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